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ABSTRACT
Objective: Clinical isolates coproducing extended-spectrum beta-lactamase (ESBL) and Ambler Class C (AmpC) beta-lactamase are a therapeutic 
challenge. The aim of the present study was to evaluate the antibacterial activity of Azadirachta indica methanolic leaf extract against lactose 
fermenting coproducers of ESBL and AmpC isolated from skin and soft-tissue infections (SSTIs).
Methods: A total of 88 non-duplicate lactose fermenting strains isolated from SSTIs specimens were tested for their antibiotic susceptibility pattern 
by Kirby-Bauer disk diffusion method. Ceftazidime and cefoxitin-resistant strains were screened for coproduction of ESBL and AmpC beta-lactamase 
by phenotypic confirmatory disc diffusion test and E-test. Antibacterial activity of methanolic neem leaf (NLM) extract was examined by the disc 
diffusion method and the minimum inhibitory concentration (MIC) of NLM was determined by the agar dilution technique.
Results: Thirty-seven lactose fermenting strains were confirmed to be coproducers of ESBL and AmpC, out of which 27 were Escherichia coli and 10 
were Klebsiella spp. The nimbin content in the neem leaf extract was found to be 0.007% (w/w) by high-performance liquid chromatography (HPLC) 
analysis. The NLM extract showed inhibitory activity against all the 37 lactose fermenting isolates from SSTIs, coproducing ESBL and AmpC. The MIC 
of NLM extract was determined to be in the range of 4–8% (40–80 mg/ml) against the selected isolates.
Conclusion: It can be stated that NLM extract might have therapeutic significance against coproducers of ESBL and AmpC beta-lactamase isolated 
from SSTIs.
Keywords: Extended-spectrum beta-lactamase, Ambler Class C, Azadirachta indica, Skin and soft-tissue infections, E-test, High-performance liquid 
chromatography.
INTRODUCTION
Beta-lactam antibiotics are among the most commonly used 
antimicrobials in the world. Extended-spectrum beta-lactamases 
(ESBLs) are clavulanate susceptible enzymes that hydrolyze 
penicillins, expanded-spectrum cephalosporins, and monobactams 
and are commonly inhibited by beta-lactamase inhibitors such as 
clavulanic acid, sulbactam, and tazobactam [1]. Ambler Class C (AmpC) 
beta-lactamases are cephalosporinases that are poorly inhibited 
by clavulanic acid. They can be differentiated from ESBLs by their 
ability to hydrolyze cephamycins as well as other extended-spectrum 
cephalosporins [2]. The rapid emergence of Gram-negative bacteria 
coproducing ESBL and AmpC beta-lactamase pose a challenge in 
therapeutics, as they mask each other, making their detection difficult. 
They also cause an increase in the minimum inhibitory concentrations 
(MIC) of beta-lactam antibiotics and create limitations in the selection 
of antimicrobial agents [3].
Skin and soft-tissue infections (SSTIs) are the general term used for 
infections of the entire skin layer, including the subcutaneous and 
muscle tissue layers and their respective fascia structures. In India, 
SSTIs may contribute to longer hospital stays, increase the cost 
of medical care, and play an important role in the development of 
antimicrobial resistance [4]. Increasing resistance to the beta-lactam 
group of antibiotics by the Gram-negative pathogens has led to the 
search of new antimicrobials, from natural products and secondary 
metabolites of the medicinal plants. After the substantiation of 
pharmacological effects, medicinal plants can act as natural sources for 
compounds that could be effective as new antimicrobial agents.
Azadirachta indica (neem) belongs to Meliaceae family and is a very 
important medicinal plant which is traditionally used to treat different 
diseases. Almost every part of the tree has been used in traditional system of 
medicine for the treatment of a variety of human ailments. It has remarkable 
anti-inflammatory, antibacterial, and antifungal properties [5]. It has been 
found that neem includes a vast array of biologically active compounds that 
are chemically diverse and structurally complex. More than 140 compounds 
have been isolated from different parts of neem. The antibacterial activity 
of neem might be due to the presence of triterpenoids - bitters, phenolic 
compounds, carotenoids, steroids, and tetratriterpenoids- azadirachtin [6].
This study aims to investigate the antibacterial activity of methanolic 
neem leaf (NLM) extract against lactose fermenting coproducers of 
ESBL and AmpC isolated from SSTIs.
METHODS
The present study was conducted in a tertiary care hospital and was 
approved by the local ethics committee of the institution.
Bacterial strains
A total of 88 non-duplicate lactose fermenting strains isolated from 
SSTIs of patients from our tertiary care hospital were selected for the 
study. The samples were processed, and the isolates were identified as 
per standard laboratory methods [7].
Antimicrobial susceptibility test (AST)
The antimicrobial susceptibility was determined by Kirby-Bauer disk 
diffusion method in accordance with the Clinical and Laboratory 
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Standards Institute (CLSI) guidelines using commercially available 
antimicrobial discs (HiMedia, Mumbai, India) [8]. The following 
antibiotics were used - ampicillin (10 μg), amikacin (10 μg), ciprofloxacin 
(5 μg), gentamicin (10 μg), amoxyclav (30 μg), ceftazidime (30 μg), 
cefoxitin (30 μg), imipenem (10 μg), and piperacillin-tazobactam 
(100/10).
The turbidity of the isolates was adjusted to 0.5 McFarland standards 
for all the tests. All the isolates which were resistant to ceftazidime 
and cefotaxime, as per the CLSI susceptible breakpoints were further 
screened for confirmation of ESBL and AmpC production.
Phenotypic confirmatory disc diffusion test (PCDDT)
The current CLSI guideline does not describe any method for 
detection of isolates producing AmpC beta-lactamases. Ceftazidime 
(30 μg) - ceftazidime/clavulanic acid (30/10, HiMedia, Mumbai, 
India) was used for ESBL detection. If there was ≥5 mm increase in 
the inhibition zone diameter of ceftazidime/clavulanic acid versus 
ceftazidime alone, the isolate was considered as an ESBL producer 
[8]. Cefoxitin (CX 30µg) - Cefoxitin/Cloxacillin (30/200, HiMedia, 
Mumbai, India) discs were used for AmpC detection. An increase of 
≥4 mm in the inhibition zone diameter of cefoxitin/cloxacillin acid 
versus cefoxitin alone indicated AmpC production [9].
E-test
Detection by phenotypic testing may be misleading, especially when 
there is a coexistence of ESBL and AmpC. They mask each other, which 
results in misreporting and failure in the clinical treatment of patients. 
For this reason, E-strips which differ from conventional strips have 
been used. Different inhibitors have been applied to improvise the 
phenotypic tests for beta-lactamase detection.
ESBL and AmpC detection Ezy MICTM strip (EM081, HiMedia, Mumbai, 
India) are drug-impregnated strips in which upper half contains a 
concentration gradient of four antibiotics; ceftazidime, cefotaxime, 
cefepime, and cloxacillin plus clavulanic acid and tazobactam and 
lower half contains of ceftazidime, cefotaxime, cefepime, and cloxacillin 
in a concentration gradient in a reverse direction. The isolates were 
reported and confirmed as ESBL and AmpC beta-lactamase producer 
as per the application sheet supplied by the manufacturer. These strips 
are to be used along with pure ESBL detection strips (EM079 HiMedia, 
Mumbai, India) to avoid false positive results [8-11].
A standard reference strain of Escherichia coli ATCC 25922, susceptible 
to all antimicrobial drugs tested, and positive control strain Klebsiella 
pneumoniae ATCC 700603 was used as a quality control for AST, 
confirmatory phenotypic disc diffusion test, and the E-test, as per CLSI 
guidelines. These phenotypically confirmed coproducers of ESBL and 
AmpC were selected as test strains, for further studies.
Preparation of NLM extract
Fresh A. indica leaves were purchased from local market. The collected 
leaves were identified and authenticated by a Botanist at K.C. College, 
Mumbai. The leaves were separated, washed, and dried in shade. 
10 grams of dried and grounded leaves were transferred into a flask 
containing 150 ml of methanol and Soxhlet extraction was carried out. 
The extract was filtered and the solvent was evaporated. The dried 
powder obtained after solvent evaporation was dissolved in 50% 
dimethyl sulfoxide (DMSO) to obtain a concentration of 500 mg/ml. 
The prepared extract was stored at 4°C for further use in the study after 
sterility testing of the extract [12,13].
High-performance liquid chromatography analysis (HPLC)
The HPLC system consisted of a Shimadzu LC-2010 CHT model 
(Shimadzu, Tokyo, Japan), with a C18-packed with silanized 
octadecylsilyl silica gel, 0.5 µ size, 250 mm × 4.6 mm (Merck) stainless 
steel column. 20 μl of the prepared sample was injected into the HPLC 
column for the analysis. The elution was carried out at a flow rate of 
1.2 ml/min using the gradient proportion of 100% acetonitrile and 
buffer as the mobile phase. For the preparation of buffer, dissolve 
0.136 g of anhydrous potassium dihydrogen orthophosphate (KH2PO4) 
in 900 ml of HPLC grade water and add 0.5 ml of orthophosphoric acid. 
Make up the total volume to 1000 ml with HPLC grade water, filter 
through 0.45 µ membrane and degas in a sonicator for 3 min (Natural 
Remedies, Bangalore, India).
Antibacterial activity of NLM extract
The evaluation of antibacterial activity of NLM was conducted by the 
disc diffusion method using Mueller-Hinton agar as described by the 
CLSI [8]. Sterile paper discs (6 mm, HiMedia, Mumbai, India) were 
impregnated with 20 μl of the 500 mg/ml NLM extract and placed on 
the inoculated agar. For the positive control, a disc of imipenem (10 μg) 
and for negative control, a disc impregnated with DMSO was placed on 
the inoculated Mueller-Hinton agar. The plate was incubated at 37°C for 
24 h. The experiment was performed in triplicate [13].
Determination of MIC
The MIC of NLM extract was determined by agar dilution method [14]. 
For MIC of NLM extract, dilutions were prepared by mixing NLM extract 
with sterile Mueller-Hinton agar to get final concentrations ranging 
between 0.25% and 8% (2.5–80 mg/ml). A plate of Mueller-Hinton 
agar with DMSO served as a control. These plates were seeded with 
bacterial suspensions and were incubated at 37°C for 24 h. The MIC 
was recorded as the lowest concentration of NLM extract at which 
visible bacterial growth was completely inhibited. The experiment was 
performed in triplicate [13,14].
Using the Student’s t-test, significance of the difference between the 
mean of zone of inhibition (ZOI) of the NLM extract against E. coli and 
Klebsiella spp. was statistically evaluated.
RESULTS
Among the 88 lactose fermenting strains isolated from SSTIs, 59 isolates 
were identified as E. coli and 29 as Klebsiella spp. Out of the 88 lactose 
fermenting isolates from SSTIs, 78.4% (69/88) isolates were found to 
be beta-lactamase producers. Resistance to ceftazidime and cefoxitin 
was indicative of ESBL and AmpC production, respectively, which was 
further confirmed by PCDDT and E-test. 42% (37/88) of the isolates 
were confirmed to be coproducers of ESBL and AmpC, and these were 
used as test strains further in the study. Among all the 37 test strains, 
there were 27 E. coli and 10 Klebsiella spp. isolates. Thus, in the current 
study, 45% (27/59) of E. coli and 34% (10/29) of K. pneumoniae isolates 
were coproducers of ESBL and AmpC producers.
The AST studies of the test strains revealed that carbapenems and 
aminoglycosides were the most effective antibiotics against the 
ESBL and AmpC coproducers. All the test strains exhibited a higher 
resistance rate toward quinolones in comparison with carbapenems 
and aminoglycosides. Among the two beta-lactamase inhibitors, 
piperacillin-tazobactam was more effective than amoxyclav against all 
the test strains. All the coproducers of ESBL and AmpC were also found 
to be multidrug-resistant, i.e., they were resistant to three or more than 
three groups of antibiotics (Fig. 1).
The estimation of active ingredient, nimbin was carried out by HPLC 
analysis and was found to be 0.007% (w/w). Primary screening for 
in vitro antibacterial activity of NLM extract was carried out by disc 
diffusion method. The extract showed activity against all the 37 lactose 
fermenting isolates from SSTIs, coproducing ESBL and AmpC. The 
average ZOI was in the range of 07–13 mm with a mean of 10.4 ± 2.33 mm 
against the test strains. No ZOI was seen for DMSO used as control. The 
average ZOI for E. coli isolates was found to be 10.72 ± 2.11 mm and 
whereas for Klebsiella spp. isolates it was 10.37 ± 2.33 mm (Fig. 2).
The MIC of NLM extract was determined by the agar dilution method. The 
MIC of NLM extract against all the 37 test strains was found to be in the 
range of 4–8% (40–80 mg/ml), as revealed in Table 1, with a mean of 
7.32 ± 1.35% (73.2 mg/ml). The average MIC for E. coli isolates was 
evaluated to be 7.39 ± 1.29% and 7.32 ± 1.35% for Klebsiella spp.
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The above table depicts the number and percentage of lactose 
fermenting isolates inhibited by various minimal concentrations of 
NLM extract (n=37).
Based on ZOI, the difference in antibacterial activity of NLM extract 
against E. coli and Klebsiella spp. was statistically insignificant 
(*p>0.05). Thus, the antibacterial activity of NLM extract was found to 
be equivalent for E. coli and Klebsiella spp. isolates, coproducing ESBL 
and AmpC from SSTIs.
DISCUSSION
Gram-negative bacilli producing multiple beta-lactamases are very 
complex antibiotic-resistant pathogens to control and treat. The study 
of the pattern of bacterial resistance in clinical isolates is important 
for epidemiological and therapeutic purposes. In the current study, 
the principal mechanism of beta-lactam resistance was found to 
be coexpression of ESBL and AmpC beta-lactamases in E. coli and 
Klebsiella spp. In this study, imipenem was established as the most 
effective antibiotic for strains which coproduce ESBL and AmpC, 
followed by aminoglycosides, amikacin, and gentamicin. The resistant 
rate in the test strains toward third-generation cephalosporins was in 
accordance with the study carried out by Afroz et al. [15]. The prevalence 
rate of the coproduction of ESBL and AmpC in lactose fermenters was 
well-corroborated by a similar study conducted in Mumbai, by Shinde 
et al. [16].
In the recent past, due to the multidrug-resistance exhibited by 
coproducers of ESBL and AmpC, carbapenems had been the drug 
of choice for serious infections [17]. In the current study, all the test 
strains were multidrug-resistant, but were sensitive to carbapenems, 
justifying their usage in empirical therapy. However, carbapenem-
resistant strains are rapidly emerging; suggesting monitored usage 
of carbapenems in therapeutics. It is a known fact that beta-lactam 
inhibitors are ineffective against AmpC producers under in vivo 
conditions. Conversely, sometimes, false susceptibility patterns are 
observed, particularly in incidences of coexpression beta-lactamases, 
leading to erroneous treatment choices [18]. A significant observation 
of the existing study was the false susceptibility against piperacillin-
tazobactam, in vitro by ESBL and AmpC coproducers. This combination 
would presumably not be effective under in vivo conditions for isolates 
producing AmpC. Thus, this evidence suggests that detection of AmpC 
along with ESBL producers should be performed routinely in the 
hospitals, to avoid therapeutic failure.
The increasing failure of antibiotics has led to the screening of 
several plant extracts for their potential antimicrobial activity. The 
antimicrobial activity of neem leaves has been majorly attributed to 
bitters like nimbin, which was found in NLM extract in this study [19]. 
The antibacterial activity of NLM extract was studied using disc diffusion 
test, and it inhibited all the test strains indicating a potent antibacterial 
activity against the resistant isolates. Our results are in agreement with 
the findings of previous studies of Koona and Budida [6] and Chaturvedi 
et al. [20].
In the current study, the average MIC of NLM extract against the 
test strains was higher in comparison to the beta-lactam sensitive 
isolates selected in the study by Dahiya et al. [21] and Emmanuel et 
al. [22]. In another previous study reported by Shah et al., the MIC 
values against pure ESBL and pure AmpC producers were also found 
to be comparatively lower than the current study [13]. On the basis of 
above comparisons, it can be suggested that a higher concentration of 
NLM extract is required for inhibition of ESBL and AmpC coproducers. 
Thus, the higher MIC values in the current study against the selected 
test strains may be attributed to multiple beta-lactamase production.
There is a paucity of information on antibacterial activity of neem leaves 
against coproducers of ESBL and AmpC. To the best of our knowledge, 
the study of antibacterial activity of neem leaf against coproducer of 
ESBL and AmpC from SSTIs has not been reported earlier.
CONCLUSION
The evidence summarized above, tentatively suggests neem leaves 
may have the ability to curb the growing menace of antibiotic-resistant 
bacteria. The in vitro study proved that NLM extract inhibited lactose 
fermenting coproducers of ESBL and AmpC isolated from SSTIs. 
Further, large-scaled and well-designed clinical trials are required to 
provide more conclusive proof of antimicrobial efficacy of NLM extract. 
Additional investigation on neem leaves can increase the isolation of 
the newer molecules which will be helpful for the treatment of SSTIs.
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30 40 50 60 70 80 90
Number of strains 
inhibited
- 4 1 2 2 28 -
Percentage of strains 
inhibited
- 10.8 2.7 5.4 5.4 75.7 -
NLM: Methanolic neem leaf, MIC: Minimum inhibitory concentration, 
ESBL: Extended-spectrum beta-lactamase
Fig. 1: Rate of antibiotic resistance in E.coli and 
Klebsiella spp. (n=88). AK – amikacin, AMC – amoxyclav, 
AMP – ampicillin, CAZ – ceftazidime, CIP – ciprofloxacin, 
CX – cefoxitin, GEN – gentamicin, IMP – imipenem, and 
PIT – piperacillin-tazobactam
Fig. 2: Mean of zone of inhibition of methanolic neem leaf extract 
against coproducers of extended-spectrum beta-lactamase and 
AmpC (data are expressed as mean ± SEM, n=3)
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